This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

England

Relapsed/Refractory Hodgkin Lymphoma adult patients

Pre-ASCT:

Funded

Post-ASCT:

Funded

Reuse:

Funded

Consolidation:

Not funded (available via IFR/private funding)

Relapsed/Refractory systemic Anaplastic Large Cell Lymphoma adult patients

Funded in R/R sALCL adult patients who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Landmark NICE recommendation sees Takeda’s ADCETRIS become the first medicine to move from the new CDF to baseline commissioning for the treatment of patients with transplant naïve CD30+ R/R HL

Dr Graham Collins (Oxford), who took part in the CDF data collection exercise, explained the high response rate by saying that it "reflects the fact that we really do want, as practising haematologists, access to these agents for our patients and I think that we all accept that we need to engage in these processes otherwise it won't be made available."

Dr Stephen Robinson (Bristol): "Data from across the UK has demonstrated that (ADCETRIS) is an effective bridging strategy… It means that, for our patients, we have a very useful, relatively non-toxic agent that we can use in the 2nd salvage setting."

Relapsed/Refractory systemic Anaplastic Large Cell Lymphoma patients

Professor Tim Illidge

Professor Tim Illidge,
The University of Manchester, UK

“I am delighted that patients can maintain long term access to brentuximab vedotin through this NICE decision. Relapsed and Refractory Anaplastic Large Cell Lymphoma is an aggressive lymphoma that in the past has carried an extremely poor prognosis when initial therapy has failed and patients would succumb to their disease in a short period. Brentuximab vedotin has transformed the outlook for such patients since it was made available on the CDF and provides hope of long term survival and improved quality of life.”

Northern Ireland

Relapsed/Refractory Hodgkin Lymphoma adult patients

Pre-ASCT:

Funded

Post-ASCT:

Funded

Reuse:

Refer to local NHS service guidance for further information on funding.

Consolidation:

Not funded (available via IFR/private funding)

Relapsed/Refractory systemic Anaplastic Large Cell Lymphoma adult patients

Funding pending implementation of positive NICE guidance

Scotland

Relapsed/Refractory Hodgkin Lymphoma adult patients

Pre-ASCT:

Funded

Post-ASCT:

Funded

Reuse:

Refer to local NHS service guidance for further information on funding.

Consolidation:

Not funded (available via IFR/private funding)

Relapsed/Refractory systemic Anaplastic Large Cell Lymphoma adult patients

Not funded. Available via IPTR/private funding

Wales

Relapsed/Refractory Hodgkin Lymphoma adult patients

Pre-ASCT:

Funded

Post-ASCT:

Funded

Reuse:

Refer to local NHS service guidance for further information on funding.

Consolidation:

Not funded (available via IFR/private funding)

Relapsed/Refractory systemic Anaplastic Large Cell Lymphoma adult patients

Funding pending implementation of positive NICE guidance

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.